Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nozomu Ogura
Observed name:
N. Ogura
Institutions:
Jikei University School of Medicine,
National Cancer Center Hospital
Observed institutions:
Jikei University School of Medicine,
National Cancer Centre Japan,
Saiseikai Central Hospital,
National Cancer Center Hospital
ORCID:
0009-0003-1803-2895
Observed ORCID:
0009-0003-1803-2895
OpenAlex ID:
A5077533367
[A Case of Fournier's Gangrene during Second-Line IRIS plus Bevacizumab Chemotherapy for Rectal and Anal Canal Cancer].
2022
·
Shunsuke Imamura
, Nozomu Ogura
, et al.
·
PubMed
·
6
The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma
2025
·
Kazuhiro Shiraishi
, Shun Yamamoto
, et al.
·
Esophagus
·
4
PDF
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma
2024
·
Nozomu Ogura
, Shun Yamamoto
, et al.
·
Expert Opinion on Biological Therapy
·
3
Association of the PD ‐ L1 CPS With the Efficacy of First‐Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer
2026
·
Nozomu Ogura
, Misa Ohnishi
, et al.
·
Cancer Medicine
·
2
FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma
2026
·
Nozomu Ogura
, Shun Yamamoto
, et al.
·
Esophagus
·
2
PDF
Correlation between PD-L1 CPS and clinical outcomes in patients treated with first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: A multi-center retrospective study in Japan.
2025
·
Misa Onishi
, Nozomu Ogura
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Comparison between nivolumab plus ipilimumab, FOLFOX and nivolumab plus FOLFOX therapy as first-line treatment for cisplatin-unfit advanced esophageal squamous cell carcinoma.
2026
·
Nozomu Ogura
, Shun Yamamoto
, et al.
·
Journal of Clinical Oncology
·
1
The safety and short-term efficacy of induction DCF plus nivolumab therapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.
2025
·
Momoko Sano
, Shun Yamamoto
, et al.
·
Journal of Clinical Oncology
·
1
PDF
198P The Efficacy and safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin, 5-FU therapy for resectable locally advanced esophageal squamous cell carcinoma
2024
·
N. Ogura
, S. Yamamoto
, et al.
·
Annals of Oncology
·
1
[A Case of an Advanced Intrahepatic Cholangiocarcinoma Effectively Treated by Conversion Surgery after Neoadjuvant Chemotherapy of Gemcitabine, Cisplatin and S-1].
2022
·
Nozomu Ogura
, Mai Hoshino
, et al.
·
PubMed
·
1
[A Case of Advanced Esophageal Cancer Discovered Due to Suffocation, Which Was Invasive to the Trachea and Internal Carotid Artery and Treated by Chemotherapy].
2021
·
Tomoyasu Hayashi
, Nozomu Ogura
, et al.
·
PubMed
·
1
[A Case of Recurrent Premenopausal Hormone Receptor Positive Breast Cancer with Liver, Lung and Bone Metastasis Successfully Treated with Endocrine Therapy].
2020
·
Mariko Sanbonmatsu
, Shinsuke Funakoshi
, et al.
·
PubMed
·
1
P1.116. Comparison Between Nivolumab + Ipilimumab, FOLFOX, and Nivolumab + FOLFOX Therapy as First-Line Therapy for Cisplatin-Unfit Advanced Esophageal Squamous Cell Carcinoma
2026
·
Nozomu Ogura
, Shun Yamamoto
, et al.
·
Diseases of the Esophagus
Progression of Atrioventricular Conduction Disorder Induced by Radiofrequency Ablation for Hepatocellular Carcinoma
2026
·
Rakuhei Nakama
, Miyuki Sone
, et al.
·
Cureus
Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan
2026
·
Nozomu Ogura
, Hidekazu Hirano
, et al.
·
JCO Precision Oncology
402. the Retrospective Analysis of Nivolumab Plus Folfox Therapy as the First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma
2025
·
Nozomu Ogura
, Shun Yamamoto
, et al.
·
Diseases of the Esophagus
PDF
421P Prognostic impact of the modified Glasgow prognostic score in advanced gastric and gastroesophageal junction cancer treated with first-line nivolumab plus chemotherapy: A multi-center retrospective study
2025
·
N. Ogura
, M. Onishi
, et al.
·
Annals of Oncology
427P Safety and efficacy of nivolumab plus chemotherapy in patients with advanced gastric cancer with ascites: A multi-center retrospective study in Japan
2025
·
M. Onishi
, M. Furuta
, et al.
·
Annals of Oncology
PDF
420P Impact of early tumor shrinkage as a prognostic predictor in patients treated with first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: A multi-center retrospective study in Japan
2025
·
R. Inamoto
, N. Takahashi
, et al.
·
Annals of Oncology
PDF
426P The strategy of planned discontinuation of oxaliplatin for advanced gastric cancer treated with nivolumab plus chemotherapy: A multi-center retrospective study
2025
·
M. Furuta
, M. Onishi
, et al.
·
Annals of Oncology
PDF
Correlation between immune-related adverse events and clinical outcomes in patients treated with first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: A multi-center retrospective study in Japan.
2025
·
Rin Inamoto
, Nozomu Ogura
, et al.
·
Journal of Clinical Oncology
PDF
Third-line S-1 or FOLFOX treatment in advanced pancreatic cancer who received gemcitabine+nab-paclitaxel and nanoliposomal-irinotecan+5-fluorouracil/leucovorin
2025
·
Tomomi Sanomachi
, Akihiro Ohba
, et al.
·
Research Square
PDF
Comprehensive genomic profiling of advanced anal adenocarcinoma.
2024
·
Nozomu Ogura
, Hidekazu Hirano
, et al.
·
Journal of Clinical Oncology
P19-10 A case of non-invasive therapy for unresectable desmoid fibromatosis with perforation of the gastrointestinal tract
2023
·
Hiroaki Miyake
, Koji Iwashita
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
24
Citation count:
24
H-index:
3
I10-index:
Year
Topic
Type